{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:13:19Z","timestamp":1793196799291,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jdin.2025.09.022","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:25:25Z","timestamp":1766420725000},"page":"28-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b\/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)"],"prefix":"10.1016","volume":"25","author":[{"given":"Kristina Callis","family":"Duffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Balagula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ming","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dyme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdin.2025.09.022_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jdin.2025.09.022_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jdin.2025.09.022_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jdin.2025.09.022_bib4","series-title":"Sotyktu [Package Insert]","year":"2022"},{"key":"10.1016\/j.jdin.2025.09.022_bib5","series-title":"Sotyktu [Package Insert]","year":"2022"},{"key":"10.1016\/j.jdin.2025.09.022_bib6","series-title":"Sotyktu [Product Monograph]","year":"2022"},{"key":"10.1016\/j.jdin.2025.09.022_bib7","series-title":"Sotyktu [Product Information]","year":"2022"},{"key":"10.1016\/j.jdin.2025.09.022_bib8","series-title":"Sotyktu [European Summary of Product Characteristics]","year":"2023"},{"key":"10.1016\/j.jdin.2025.09.022_bib9","series-title":"Sotyktu [Package Insert]","year":"2023"},{"key":"10.1016\/j.jdin.2025.09.022_bib10","series-title":"Sotyktu [Package Insert]","year":"2023"},{"key":"10.1016\/j.jdin.2025.09.022_bib11","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.jdin.2025.09.022_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, program fOr evaluation of TYK2 inhibitor psoriasis second phase 3 trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000232309","article-title":"Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm\/soles and nails","volume":"38","author":"Kragballe","year":"2009","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib15","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaad.2008.11.890","article-title":"Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation","volume":"60","author":"Chan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib17","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1468-3083.2007.02424.x","article-title":"Scalp psoriasis: a review of current topical treatment options","volume":"21","author":"Papp","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2025.09.022_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/09546634.2012.681017","article-title":"Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council","volume":"24","author":"Kragballe","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jdin.2025.09.022_bib19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2023.11.060","article-title":"Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis","volume":"90","author":"Blauvelt","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/24755303231160683","article-title":"Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities","volume":"8","author":"Blauvelt","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"10.1016\/j.jdin.2025.09.022_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jdin.2025.09.022_bib22","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/jdv.13700","article-title":"Prevalence of psoriatic arthritis and its correlates among patients with psoriasis in Greece: results from a large retrospective study","volume":"30","author":"Papadavid","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2025.09.022_bib23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/bjd.12393","article-title":"Topical treatments for chronic plaque psoriasis of the scalp: a systematic review","volume":"169","author":"Mason","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib25","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jdv.12996","article-title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","volume":"29","author":"Langley","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2025.09.022_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/09546634.2016.1249820","article-title":"Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"28","author":"Reich","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jdin.2025.09.022_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/jdv.12553","article-title":"Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study","volume":"29","author":"Tha\u00e7i","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2025.09.022_bib28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12589","article-title":"Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails","volume":"31","author":"Merola","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jdin.2025.09.022_bib30","article-title":"VISIBLE Cohort B: guselkumab demonstrates significant scalp clearance at week 16 in participants with moderate-to-severe scalp psoriasis across all skin tones","volume":"191","author":"Alexis","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/09546634.2019.1577546","article-title":"Qualitative analysis and reproducibility assessment of the scalp itch numeric rating scale among patients with moderate to severe plaque psoriasis of the scalp","volume":"30","author":"Wang","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jdin.2025.09.022_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3 years: an open-label extension of randomized clinical trials","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jdin.2025.09.022_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328725001877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328725001877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:27:40Z","timestamp":1775028460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328725001877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"alternative-id":["S2666328725001877"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2025.09.022","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b\/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2025.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}